Proteomics Analysis for Therapeutic Options of Neurodegeneration: A Review

The characterization and identification of putative disease modifying pathways in neurodegenerative disorders has enormous potential for discovery of new therapeutic agents that target these pathways. There is an increasing evidence that a number ofpotentially informative Neurodegenerative Disease (NDD) biomarkers can improve the accuracy of diagnosing NDD, especially when they are used as a panel of diagnostic assays and interpreted in the context of neuroimaging and clinical data. The greatest contributing risk factor for NDDs is age. With an aging population, the inevitable result is a steep rise in the incidence of NDDs. The first publication that reported about Alzheimer disease (AD) was in 1907, which described a woman in her middle age that had lost her memory with a progressive loss of cognitive functions.

James Parkinson in 1817 was the first one who described medically a neurological syndrome and it was known as Parkinson's disease. In 1912, the lewy body that characterized the Parkinson’s disease was reported by Forman et al. Protein aggregation and inclusion body formation that was mostly associated with many forms of neurodegenerative diseases were detected using different techniques in the last century. These suggested that changes in physicochemical properties of the proteins in human brain were responsible for and lead to neurodegenerative diseases.(Read More)